Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0018801 (heart failure)
 72,216 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Recently, a significant activity of inducible nitric oxide synthase (iNOS) has been reported in biopsies from failing hearts due to idiopathic dilated cardiomyopathy (IDC). Thus, a potential pathophysiological role of iNOS in IDC has been stated. In order to investigate, whether iNOS expression is of pathophysiological relevance in human heart failure, we measured iNOS protein expression and cGMP content in left ventricular myocardium from non-failing and failing human hearts. Immunoblot analysis revealed iNOS protein expression in four out of six failing hearts from septic patients, whereas no iNOS-protein expression was detected in either non-failing human hearts (n = 6) or failing hearts due to IDC (n = 9), ischemic heart disease (IHD, n = 7), Becker muscular dystrophy (BMD, n = 2) and mitoxantrone-induced toxic cardiomyopathy TCM, n = 1). cGMP content was increased by 130% in septic hearts, whereas there was no cGMP increase in hearts with IDC. IHD and BMD compared to non-failing hearts. We conclude, that the induction of iNOS may play a role in contractile dysfunction observed in septic shock, but is unlikely to be of major pathophysiological importance in end-stage heart failure due to IDC, IHD, BMD and TCM.
 ...
PMID:Expression of inducible nitric oxide synthase in failing and non-failing human heart. 874 24

The authors retrospectively reviewed their institution's experience with extracorporeal life support (ECLS) for adult cardiovascular failure to determine efficacy and further indications for its use. From 1985 to 1996, venoarterial ECLS was used in 27 adult patients. Indications for ECLS included post cardiotomy cardiac failure, primary myocardial failure, bridge to transplant, and emergency cardiopulmonary resuscitation. The average age was 38.7 +/- 2.7 years and duration of support was 164.0 +/- 26.8 hr. Overall cardiovascular recovery from ECLS was 44%, and hospital survival was 30%. Late deaths were due to multisystem organ failure. Best results were obtained in patients whose processes were reversible during a short duration of ECLS (< 91.6 +/- 33.3 hr. The worst results were obtained in post cardiotomy patients who underwent prolonged support with ECLS. Evaluation of physiologic parameters during the first 30-48 hr of support showed marked improvements from values before ECLS. Because of its relative ease of deployment and its rapid correction of acute physiologic derangements, ECLS can be used as a temporary means of support to determine extent and reversibility of organ dysfunction. Longer term support should include consideration of other mechanical assist devices. The authors no longer consider bridge to transplant an indication for ECLS due to relative donor unavailability.
 ...
PMID:Extracorporeal life support for cardiovascular support in adults. 894 96

Duchenne and Becker muscular dystrophies (DMD and BMD, respectively) are the most common inherited muscular diseases and caused by mutations in the dystrophin gene. Half to two-thirds of DMD and BMD patients carry deletions (usually of several kilobases of genomic DNA). The clinical progression in DMD and BMD patients with deletions can be predicted in 92% of cases based on whether the deletion maintains or disrupts the translational reading frame (frame-shift hypothesis). However, some exceptional cases have been reported; BMD cases whose dystrophin gene exons 3 to 7 were deleted (out-of-frame), more severe case whose dystrophin gene deletion maintains reading frame but includes N-terminal region, and so on. Splicing mutation is one kind of mutations of dystrophin gene, and usually induced by small mutation of exon-intron boundary sequence. However, intraexonal small mutation also induces exon skipping, due to disruption of exon recognition sequence, which is intraexonal sequence and necessary for splicing of the upstream intron. For molecular diagnosis of DMD/BMD it is important to analyze not only in genomic DNA level, but also in mRNA, protein, and clinical levels. And the relationship between molecular abnormality and clinical phenotype should be examined, especially when extramuscular symptoms (heart failure and mental retardation) are prominent.
 ...
PMID:[Molecular genetics and problems found in genetic diagnosis of Duchenne Becker muscular dystrophy]. 943 21

Duchenne/Becker muscular dystrophies (DMD/BMD) are the most common inherited muscular disease and caused by mutations in the dystrophin gene. A half to two-thirds of DMD and BMD patients carry deletions (usually of several kilobases of genomic DNA). The clinical progression in DMD and BMD patients with deletions can be predicted in 92% of cases based on whether the deletion maintains or disrupts the translational reading frame (frame-shift hypothesis). However, some exceptional cases have been reported in which some posttranscriptional modifications were suggested, such as alternative splicing and reinitiation of translation. Splicing mutation is one kind of mutations of dystrophin gene, and usually induced by a small mutation of exon-intron boundary sequence. However, intraexonal small mutation also induces exon skipping, due to disruption of an exon recognition sequence, which is an intraexonal sequence and necessary for splicing of the upstream intron. Carrier diagnosis is one of the important clinical application of genetic diagnosis. In the case of DMD/BMD with deletions of the dystrophin gene, carrier diagnosis is difficult because of the existence of normal X chromosome. In these cases a linkage analysis is useful, and in some cases non-carriers can be directly diagnosed on the basis of microsattelite polymorphism detected in deleted region of patient. For the molecular diagnosis of DMD/BMD it is important to analyze not only at the genomic DNA level, but also at the mRNA, protein, and clinical levels. And the relationship between the molecular abnormality and clinical phenotype should be examined, especially extramuscular symptoms such as heart failure and mental retardation.
 ...
PMID:[Genetic diagnosis of Duchenne/Becker muscular dystrophy; clinical application and problems]. 954 79

In obstetrics and gynaecology we care for women who will die during pregnancy, for women who have fatal diseases such as autoimmune diseases or renal, liver, or cardiac failure where our care is tangential but critical to palliation, and for women dying with gynaecological malignancies. Understanding the history of the development of hospice and palliative care, as well as the ethical framework for these choices, may allow us to understand better the difficulties we face in our modern settings in making the choice to turn our goals from prolonging life to maximal comfort on the path to death. Obstetrician gynaecologists have a responsibility to be a voice of advocacy for maximal palliative care for not only the women they care for, but also for women worldwide because of their diminished social status and poverty.
Best Pract Res Clin Obstet Gynaecol 2001 Apr
PMID:End of life care: history and the role of the obstetrician and gynaecologist. 1135 97

Cardiac diseases account for almost 50% of deaths in long-term dialysis patients. Left ventricular dysfunction is present in approximately 80% of these patients and is highly predictive of future ischemic heart disease, cardiac failure, and death. Anemia has been identified as one of several risk factors responsible for cardiac complications. Cardiovascular consequences of renal anemia begin relatively early in the course of renal failure and progress with the decline of renal function and also during dialysis therapy. In chronic renal failure patients with severe anemia (hemoglobin levels <10 g/dL), increased cardiac output, high left ventricular mass, left ventricular end-diastolic and end-systolic diameters, and cardiac symptoms improve after partial correction of anemia (hemoglobin levels >11 g/dL according to the European Best Practice Guidelines). It is disappointing that normalization of hemoglobin levels has only minor effects with respect to regression of left ventricular hypertrophy and left ventricular dilation. There is no benefit of hemoglobin normalization on all-cause mortality of dialysis patients or on survival of end-stage renal disease patients with congestive heart failure or ischemic heart disease. Therefore, prevention of renal anemia may be more efficient than its treatment. Hypertension is one of the major side effects of recombinant human erythropoietin (rHuEPO) therapy. Multiple factors are involved in rHuEPO-induced hypertension. High blood pressure can usually be controlled readily in the majority of the patients.
 ...
PMID:Effect of erythropoietin on cardiovascular diseases. 1157 16

The wider availability of recombinant human growth hormone and insulin-like growth factor-I has resulted in an investigation into the potential benefits of the pharmacological administration of these anabolic peptides in a variety of clinical conditions, characterized by an increase in catabolic rate. The initial studies were small, often uncontrolled open investigations, but investigators have more recently concentrated on larger, controlled multi-centre trials. Studies to date have included patients with cardiac failure, sepsis, burns, cancer cachexia, end-stage renal failure, trauma and AIDS, and those prior to or following major surgery. The authors have in general cautiously interpreted positive effects of treatment with growth hormone and insulin-like growth factor-I, either alone or in combination, on net protein balance, body composition, well-being and performance. Two large, randomized, placebo-controlled European multi-centre studies have recently detailed the effects of growth hormone treatment in critically ill intensive care patients. Major increases in mortality and morbidity were associated with growth hormone treatment. The mechanism(s) accounting for the increased mortality remain poorly understood. These negative findings have led to a decrease in the clinical use of growth hormone and in research activity in the area of anabolic treatment in human illness.
Best Pract Res Clin Endocrinol Metab 2001 Dec
PMID:Treatment with growth hormone and insulin-like growth factor-I in critical illness. 1180 May 16

Malnutrition is more common in elderly persons than in younger adults. Ageing itself, however, neither leads to malabsorption nor to malnutrition with the exception of a higher frequency of atrophic gastritis in older persons. Malnutrition in elderly people is therefore a consequence of somatic, psychic or social problems. Typical causes are chewing or swallowing disorders, cardiac insufficiency, depression, social deprivation and loneliness. Undernutrition is associated with a worse prognosis and is an independent risk factor for morbidity and mortality. Awareness of this problem is therefore important. For the evaluation of nutritional status, it must be remembered that most normal values are derived from younger adults and may not necessarily be suitable for elderly persons. Suitable tools for evaluating the nutritional status of elderly persons are e.g. the body mass index, weight loss within the last 6 months, the Mini Nutritional Assessment (MNA) or the Subjective Global Assessment (SGA). An improvement in the nutritional status can be achieved by simple methods such as the preparation of an adequate diet, hand feeding, additional sip feeding or enteral nutrition.
Best Pract Res Clin Gastroenterol 2001 Dec
PMID:Nutrition in the elderly. 1186 82

Effective management of iron overload in thalassaemia requires monitoring both for iron toxicity and the effects of excessive chelation. Careful monitoring together with adherence to established regimens using desferrioxamine (DFO) results in a 78% survival rate at 40 years of age at UCLH, with steadily improving survival as progressive cohorts receive chelation earlier in life. By contrast, survival is considerably below this in non-specialist centres. The prognostic significance of the measures being used in monitoring should be known so that decisions about chelation management are evidence-based. Serum ferritin measurement, although easy to perform frequently, is subject to variability and falsely high or falsely low values in relation to body iron are frequently obtained. However, there is evidence that persistently high ferritin values above 2500 microg/l have poor prognostic significance in patients treated with DFO. Liver iron predicts total body iron in a more predictable way than serum ferritin in thalassaemia. Liver iron concentrations of 15 mg/g dry weight appear to predict those patients who develop heart failure in subjects treated with DFO. The prognostic significance of this measurement or indeed other measurements of iron overload in patients treated with other chelation regimens is not known. Recent advances with MRI imaging have aroused interest in its use for monitoring patients with thalassaemia. A recent publication suggests a relationship between left ventricular ejection fraction and cardiac T2*, the value of which shortens with increasing iron concentrations in the liver and hence by inference in the heart. The prognostic value of this technique has not yet been demonstrated in prospective studies and hence changes in therapy based on this measurement alone should be considered with caution at this time. The value of monitoring to decrease morbidity from iron overload is also discussed, particularly with reference to the estimation of iron deposition in the pituitary.
Best Pract Res Clin Haematol 2002 Jun
PMID:Monitoring chelation therapy to achieve optimal outcome in the treatment of thalassaemia. 1240 11

Shortness of breath is a common cause of consultation in the emergency unit. Therefore, it is essential to diagnose cases of cardiac failure. This may be difficult in some cases. The authors set out to assess the value of measuring brain natiuretic peptide in this context. Brain natiuretic peptide (BNP) was measured by an ultrafast method (Biosite/BMD) on arrival of 125 patients to the emergency unit. The results were then compared with the diagnoses made in the emergency unit and those of the hospital discharge summary. Nearly 18% of patients were wrongly classified in the emergency room; 1/3 were falsely diagnosed as cardiac failure and 2/3 were not recognised initially as having cardiac failure. In 90% of patients, in particular in the group wrongly considered as not having cardiac failure, BNP measurement could have helped correct the mistake. The optimal threshold value of BNP for diagnosis of cardiac failure in this study was 300 pg/mL, with positive and negative predictive values of 92.4 and 90.2%, respectively.
 ...
PMID:[Value of type B natriuretic peptide in the emergency management of patients with suspected cardiac failure. Report of 125 cases]. 1240 89


1 2 3 4 5 6 7 Next >>